Market Overview

UPDATE: Canaccord Reiterates Buy Rating, Raises PT on Amicus Therapeutics

Share:
Related FOLD
Benzinga's Option Alert Recap From March 8
Mid-Afternoon Market Update: Avinger Drops After Q4 Results; MeetMe Shares Spike Higher
Perceptive Advisors Llc Buys Neurocrine Biosciences, Aclaris Therapeutics, Galapagos NV, Sells ... (GuruFocus)

In a report published Wednesday, Canaccord Genuity reiterated its Buy rating on Amicus Therapeutics (NASDAQ: FOLD), and slightly raised its price target from $10.00 to $11.00.

Canaccord noted, “We think Q3 pivotal migalastat Fabry monoTx '011 trial data will be a strong positive catalyst and that the trial has a high chance of success. We also expect positive full Ph2 AT2220/ERT Pompe combo data in Q3/12. Our $11 target is based on a pNPV analysis.”

Amicus Therapeutics closed on Tuesday at $6.02.

Latest Ratings for FOLD

DateFirmActionFromTo
Jan 2017BairdUpgradesNeutralOutperform
May 2016Bank of AmericaInitiates Coverage onBuy
Apr 2016BairdInitiates Coverage onNeutral

View More Analyst Ratings for FOLD
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Price Target Analyst Ratings

 

Related Articles (FOLD)

View Comments and Join the Discussion!